Biotechnology company bluebird bio has formed a broad collaboration with Celgene to develop new disease-altering gene therapies in oncology. The multi-year research and development collaboration aims to apply gene therapy technology to ...
bluebird bio has received $9.3m Strategic Partnership Award from California Institute for Regenerative Medicine (CIRM) to support phase 1/2 studies of LentiGlobin to treat beta-thalassemia. bluebird bio chief medical officer David ...
Tags: bluebird bio, LentiGlobin, CIRM